BioSpace News Archive

Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, today launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.

Eiger BioPharmaceuticals, Inc. today announced that the Data Safety Monitoring Board (DSMB) recommended that investigators continue enrollment of the Peginterferon Lambda arm in the Phase 3 TOGETHER platform study.

Vaxart, Inc. (NASDAQ: VXRT) today announced that Chief Executive Officer Andrei Floroiu and Chief Scientific Officer Dr. Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference at 10:40 a.m. ET on Thursday, September 30, 2021.

Fore Biotherapeutics today announced the appointment of Kim Blackwell, M.D., as a member of the Board of Directors and R&D/Science Chair, and Sujit Basu, Ph.D., as Senior Vice President of Manufacturing and Technical Operations.

Bayer announced today the initiation of the FIND-CKD study, a multicenter, randomized, double-blind, placebo-controlled Phase III study for an investigational new use of KERENDIA® (finerenone) in addition to guideline-directed therapy, on the progression of chronic kidney disease (CKD) in patients with nondiabetic CKD

Clovis Oncology, Inc. announced that it has paid off in full at maturity the remaining $64.4 million in principal amount outstanding of its 2.50% convertible senior notes due 2021.

Imago BioSciences , Inc. today announced that it will be added to the Russell® 2000 Index as part of the planned second quarter IPO additions scheduled to join the Russell US Indexes on September 20, 2021.

Cerus Corporation (Nasdaq: CERS) today announced its participation in the Society for the Advancement of Blood Management (SABM) Virtual Annual Meeting, which is scheduled for September 22-25, 2021.

Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences.

Charles River Laboratories International, Inc. (NYSE: CRL) today released the results from its first annual Healthcare Collaboration Report